American Society of Hirudotherapy

Leech Therapy for Treating Priapism: Case Report

Asgari SA, Rostami S, Teimoori M (2017) · Iranian Journal of Public Health · 1 patient

Case-level evidence: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCase reportLeech therapy in other conditions

Study Profile

Design
single-patient case report (26-year-old single male, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran)
Patient
1
Presentation and intervention
Bilateral leech therapy with two leeches on each side of penile shaft for 2 hours, followed by one-hour break, then another cycle in same manner
Outcome
Significant pain reduction at 2-day follow-up despite persistent cavernosal swelling and tenderness; patient discharged after 3-day admission with complete resolution of pain and perineal swelling over 1 month
Follow-up duration
1 month with complete symptom resolution

Key Findings

  • Priapism resolution with bilateral leech therapy protocol
  • Two leeches per side, 2-hour cycles with 1-hour breaks
  • Significant 2-day pain reduction
  • Complete resolution over 1 month
  • Non-invasive alternative to surgical intervention

Limitations

  • Single case - hypothesis-generating only
  • No mental disorders, trauma, or sickle cell anemia present
  • Cannot quantify leech vs natural history contribution
  • Limited generalizability to common priapism etiologies
  • Off-label use beyond traditional K040187 indications

Clinical Implications

Asgari 2017 introduces hirudotherapy as a non-invasive alternative for refractory priapism management. For US clinicians under K040187, this Iranian case demonstrates extension of device indication to venous-congestion-mediated compartment syndromes outside traditional flap/replant contexts. However, the single-case design and absence of standard etiologies (trauma, sickle cell) limits clinical adoption.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.